Tokio Marine Asset Management Co. Ltd. Takes $113,000 Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Tokio Marine Asset Management Co. Ltd. bought a new position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 10,579 shares of the biopharmaceutical company’s stock, valued at approximately $113,000.

Other large investors have also recently bought and sold shares of the company. SG Americas Securities LLC bought a new stake in shares of Amicus Therapeutics during the 1st quarter worth approximately $291,000. Swiss National Bank lifted its stake in Amicus Therapeutics by 2.3% in the first quarter. Swiss National Bank now owns 434,300 shares of the biopharmaceutical company’s stock valued at $5,116,000 after acquiring an additional 9,900 shares during the last quarter. Sei Investments Co. lifted its stake in Amicus Therapeutics by 9.5% in the first quarter. Sei Investments Co. now owns 222,715 shares of the biopharmaceutical company’s stock valued at $2,624,000 after acquiring an additional 19,366 shares during the last quarter. ProShare Advisors LLC grew its position in shares of Amicus Therapeutics by 10.7% in the 1st quarter. ProShare Advisors LLC now owns 72,845 shares of the biopharmaceutical company’s stock valued at $858,000 after acquiring an additional 7,068 shares during the period. Finally, Orion Portfolio Solutions LLC increased its stake in shares of Amicus Therapeutics by 9.0% during the 1st quarter. Orion Portfolio Solutions LLC now owns 152,187 shares of the biopharmaceutical company’s stock worth $1,793,000 after purchasing an additional 12,559 shares during the last quarter.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Bank of America raised their target price on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a research note on Thursday, October 17th. Jefferies Financial Group started coverage on Amicus Therapeutics in a research report on Friday, September 6th. They issued a “buy” rating and a $18.00 price objective for the company. Needham & Company LLC restated a “hold” rating on shares of Amicus Therapeutics in a research note on Thursday, November 7th. StockNews.com raised Amicus Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday. Finally, JPMorgan Chase & Co. upped their price objective on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, November 12th. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $17.63.

Insider Buying and Selling at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $10.60, for a total transaction of $79,500.00. Following the sale, the chief executive officer now directly owns 886,654 shares in the company, valued at $9,398,532.40. This represents a 0.84 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders sold 30,401 shares of company stock valued at $352,038 in the last three months. Corporate insiders own 2.20% of the company’s stock.

Amicus Therapeutics Stock Down 4.1 %

NASDAQ FOLD opened at $9.68 on Friday. The company has a market cap of $2.89 billion, a price-to-earnings ratio of -28.47 and a beta of 0.68. Amicus Therapeutics, Inc. has a 1-year low of $9.02 and a 1-year high of $14.57. The company has a current ratio of 3.15, a quick ratio of 2.42 and a debt-to-equity ratio of 2.18. The company has a 50 day moving average of $11.00 and a 200-day moving average of $10.61.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.